关键词: 成纤维细胞生长因子21, 类似物, 动脉粥样硬化

Abstract: Atherosclerosis is the main cause of coronary heart disease, cerebral infarction and peripheral vascular disease. Incidence is increasing, which threatens human life and health seriously. Lipid metabolism disorder is the pathological basis of atherosclerosis. Fibroblast growth factor 21 (FGF21) is an endocrine factor of the FGF family. It increases glucose uptake, modulates lipid metabolism, and sensitizes insulin response in metabolically active organs, including the liver and adipose tissue. Emerging evidence showed a strong correlation between circulating FGF21 levels and the incidence and severity of atherosclerosis. However, the short plasma half-life of native FGF21 and its propensity to aggregate in vitro have limited its clinical application. Recently, breakthrough progress has been made in FGF21 analogues. The present review summarized the physiological roles of FGF21, and discussed major breakthroughs and limitations of FGF21 mimetic-based therapeutic strategies for treating atherosclerosis, which was expected to provide theoretical basis for the development of new FGF21 protein drugs.

Key words: fibroblast growth factor 21, analogue, atherosclerosis